Clear Search sequence regions


Sizes of these terms reflect their relevance to your search.

Aim: To assess the relative efficacy of disease-modifying therapies (DMTs) for relapsing multiple sclerosis (RMS) including newer therapies (ozanimod, ponesimod, ublituximab) using network meta-analysis (NMA). Materials & methods: Bayesian NMAs for annualised relapse rate (ARR) and time to 3-month and 6-month confirmed disability progression (3mCDP and 6mCDP) were conducted. Results: For each outcome, the three most efficacious treatments versus placebo were monoclonal antibody (mAb) therapies: alemtuzumab, ofatumumab, and ublituximab for ARR; alemtuzumab, ocrelizumab, and ofatumumab for 3mCDP; and alemtuzumab, natalizumab, and either ocrelizumab or ofatumumab (depending on the CDP definition used for included ofatumumab trials) for 6mCDP. Conclusion: The most efficacious DMTs for RMS were mAb therapies. Of the newer therapies, only ublituximab ranked among the three most efficacious treatments (for ARR).

Citation

Imtiaz A Samjoo, Christopher Drudge, Sarah Walsh, Santosh Tiwari, Róisín Brennan, Ibolya Boer, Dieter A Häring, Luisa Klotz, Nicholas Adlard, Judit Banhazi. Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis. Journal of comparative effectiveness research. 2023 Jul;12(7):e230016

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 37265062

View Full Text